Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma

Tumor mutational burden (TMB) is an emerging predictive marker of response to immune checkpoint inhibitor therapies. We evaluated the correlation between clinical indicators and high‐throughput sequencing results and TMB in lung adenocarcinoma patients, with the aim of finding simpler and more econo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Kai, Huang, Fengxiang, Wang, Yin, Kang, Yan, Wang, Qilong, Tang, Jiaqi, Sun, Panfeng, Lou, Jiaojiao, Qiao, Ruiping, Si, Jiming, Cao, Jian, Miao, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678101/
https://www.ncbi.nlm.nih.gov/pubmed/35521981
http://dx.doi.org/10.1002/cam4.4781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678101/
https://www.ncbi.nlm.nih.gov/pubmed/35521981
http://dx.doi.org/10.1002/cam4.4781

Ejemplares similares